Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
0.897
+0.003 (0.29%)
Jun 21, 2024, 12:43 PM EDT - Market open

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019 2018 - 1996
Market Capitalization
169191199413264133
Upgrade
Market Cap Growth
--4.09%-51.84%56.44%98.01%15.01%
Upgrade
Enterprise Value
12815814535722684
Upgrade
PE Ratio
-11.79-8.88-7.57-9.60-12.78-11.39
Upgrade
PS Ratio
21.1021.3213.5395.13144.5737.93
Upgrade
PB Ratio
2.333.012.714.482.741.18
Upgrade
P/FCF Ratio
-11.81-6.52307.85-17.28-13.34-4.13
Upgrade
P/OCF Ratio
-12.08-6.68187.79-17.53-13.36-4.17
Upgrade
EV/Sales Ratio
16.0517.699.8582.33123.6223.94
Upgrade
EV/EBITDA Ratio
-10.39-7.00-5.79-8.48-11.41-5.26
Upgrade
EV/EBIT Ratio
-10.09-6.79-5.63-8.31-10.31-4.40
Upgrade
EV/FCF Ratio
-10.10-5.41224.29-14.95-11.40-2.60
Upgrade
Debt / Equity Ratio
0.040.050.050.030.030.05
Upgrade
Debt / EBITDA Ratio
-0.14-0.13-0.16-0.07-0.17-0.32
Upgrade
Debt / FCF Ratio
-0.14-0.106.03-0.12-0.17-0.16
Upgrade
Quick Ratio
2.592.023.062.325.358.42
Upgrade
Current Ratio
2.712.143.162.375.668.86
Upgrade
Asset Turnover
0.080.080.110.030.020.02
Upgrade
Return on Equity (ROE)
-34.20%-31.30%-32.70%-37.80%-21.00%-8.90%
Upgrade
Return on Assets (ROA)
-22.10%-19.90%-19.60%-30.30%-18.70%-7.90%
Upgrade
Return on Capital (ROIC)
-32.72%-37.26%-29.16%-51.79%-26.58%-32.91%
Upgrade
Earnings Yield
-14.01%-11.26%-13.21%-10.42%-7.82%-8.78%
Upgrade
FCF Yield
-14.00%-15.33%0.32%-5.79%-7.50%-24.23%
Upgrade
Buyback Yield / Dilution
-7.51%-1.69%-3.22%-9.64%-3.10%-14.68%
Upgrade
Total Shareholder Return
-7.51%-1.69%-3.22%-9.64%-3.10%-14.68%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).